BASF to Build New World-Scale Plant for Specialty Amines in Ludwigshafen
BASF is building a new world-scale plant for the production of specialty amines in Ludwigshafen. Start-up of the facility with a total annual capacity of about 12,000 metric tons is scheduled for 2015. The product range of this flexible multi-product plant comprises 15 amines for different applications. The major applications are in the construction, automotive, crop protection and pharmaceutical industries. With this new facility, BASF is expanding its global production network of amines with plants in Ludwigshafen and Schwarzheide in Germany; Antwerp, Belgium; Geismar, Louisiana; and Nanjing, China.
“With the new plant we are responding to our customers’ demand for specialty amines, particularly in Europe,” said Sanjeev Gandhi, President, BASF Intermediates division. “We have decades of experience in developing and manufacturing amines, and with the new plant we are reinforcing our global leadership position in these versatile intermediates.”
“This facility enables us to react flexibly to changes in the demand of individual products. We will also use it to produce commercial quantities of new products from our innovation pipeline,” said Dr Christoph Wegner, head of the regional business unit Amines Europe within BASF’s Intermediates division. “Being integrated into the BASF Verbund at the Ludwigshafen site allows us to scale up products from R&D to pilot scale and to commercial production in this new multi-product plant for our customers.”
BASF had announced in March that it is building another new multi-product plant for the production of specialty amines at the BASF Verbund site in Nanjing, China. The main products of this plant, which is due to start-up operations in 2015, will be dimethylaminopropylamine (DMAPA) and polyetheramine (PEA).
With about 200 different amines, BASF has the world’s most diverse portfolio of this type of chemical intermediates. Along with alkyl-, alkanol-, alkoxyalkylamines, the company offers heterocyclic and aromatic as well as specialty amines. The range is completed by an expanding portfolio of chiral amines of high optical and chemical purity. The versatile products are used mainly to manufacture process chemicals, pharmaceuticals and crop protection products, as well as cosmetic products and detergents. They also serve to produce coatings, special plastics, composites and special fibers.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance